THE EFFECT OF OBESITY ON MORTALITY IN COVID-19 PATIENTS

Öz

The COVID-19 pandemic has caused a major global health crisis. The total number of cases detected at the global level has exceeded 200 million. It resulted in more than fourmillion deaths. Lymphopenia and impaired immune response are seen in this severe respiratory infection caused by the SARS-CoV-2 virus. It has long been known that obesity is associated with a long recovery time and worse clinical outcomes in viral infections. In creasing data on the endocrine function of adipose tissue in recent years show that obesity should be considered not only as a risk factor but also as a disease. Studies on this subject show that obese patients and their co-morbidities maybe moreprone to develop serious conditions that require hospitalization and mechanical ventilation. Studies also indicate that special attention should be paid to reduce the morbidity and mortality associated with COVID-19 infection in the presence of obesity. In this review, possible relationships between obesity and COVID-19 mortality were examined based on the above data.

Anahtar Kelimeler

• mortality
• obesity
• pandemic
• COVID-19
• SARS-CoV-2

COVID-19 HASTALARINDA OBEZİTENİN MORTALİTE ÜZERİNE ETKİSİ

Öz

COVID-19 pandemisi, küresel sağlık açısından büyük bir krize neden olmuştur. Küresel düzeyde tanımlanan toplam vaka sayısı 200 milyonu aşmıştır. Dört milyondan fazlası ölümle sonuçlanmıştır. SARS-CoV-2 virüsünün neden olduğu bu ağır solunum yolu enfeksiyonunda, lenfopeni ve bozulmuş bağışıklık tepkisi görülmektedir. Obezitenin viral enfeksiyonlarda iyileşme süresinde uzama ve daha kötü klinik sonuçlarla ilişkisi uzun zamandır bilinmektedir. Son yıllarda yağ dokusunun endokrin işlevi konusunda artan veriler obezitenin sadece bir risk faktörü değil aynı zamanda bir hastalık olarak düşünülmesi gerektiğini göstermektedir. Bu konuda yapılan çalışmalar obez hastaların ve komorbiditelerinin, hastaneye yatış ve mekanik ventilasyon gerektiren ciddi tablolar geliştirmeye daha yatkın olabildiğini göstermektedir. Çalışmalar aynı zamanda obezite varlığında COVID-19 enfeksiyonu ile ilişkili morbidite ve mortaliteyi azaltmak için özel dikkat gösterilmesi gerektiğine işaret etmektedir. Bu derlemede, yukarıdaki verilerden yola çıkarak obezite ile COVID-19 mortalitesi arasındaki olası ilişkiler incelenmiştir.

Anahtar Kelimeler

• COVID-19
• Mortalite
• Obezite
• Pandemi
• SARS-CoV-2
• mortality
• obesity
• pandemic

Kaynakça

1. Galanopoulos M, Gkeros F, Doukatas A, et al. COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract. World J Gastroenterol. 2020; 26(31):4579-4588.
2. WHO. Coronavirus (COVID-19) dash board. https://covid19.who.int/ Erişim tarihi: 25.08.2021.
3. Singh SP, Pritam M, Pandey B, et al. Microstructure, pathophysiology, and potential the rapeutics of COVID-19: A comprehensive review. J Med Virol. 2021; 93(1):275-299.
4. CiottiM, Angeletti S, Minieri M, et al. COVID-19 out break: an over view. Chemotherapy2019; 64(5-6):215-223.
5. Korakas E, Ikonomidis I, Kousathana F, et al. Obesity and COVID-19: immune and metabolic derangement as a possible link to adverse clinical out comes. J Physiol Endocrinol Metab Am. 2020; 319(1):e105-e109.
6. Malik VS, Ravindra K, Attri SV, et al. Higher body massindex is an important risk factor in COVID-19 patients: a systematicreviewand meta-analysis. Environ Sci Pollut Res. 2020; 27(33):42115-42123.
7. Sales-Peres S, de Azevedo-Silva LJ, Bonato R, et al. Coronavirus (SARS-CoV-2) and the risk of obesity for criticallyillness and ICU admitted: meta-analysis of the epidemiological evidence. Obes Res Clin Pract. 2020; 14(5):389-397.
8. Malik P, Patel U, Patel K, et al. Obesity a predictor of outcomes of COVID-19 hospitalized patients-A systematic review and meta-analysis. J Med Virol 2021; 93(2):1188-1193.

9. Alarcon PC, Damen M, Madan R, et al. Adipocyte inflammation and pathogenesis of viral pneumonias: an over looked contribution. Mucosal Immunol. 2021; 1-11. Advance online publication.
10. O'Neill LA, Kishton RJ, Rathmell J. A guide to immuno metabolism for immunologists. Nature reviews. Immunology 2016; 16(9):553-565.
11. Caci G, Albini A, Malerba M, et al. COVID-19 and Obesity: Dangerous Liaisons. J Clin Med. 2020; 9(8):2511.
12. Liu R, Nikolajczyk, BS. Tissue immune cellsfuel obesity-associated inflammation in adipose tissue and beyond. Front Immunol. 2019; 10:1587.
13. Albashir A. The potential impacts of obesity on COVID-19. J Clin Med. 2020; 20(4):109-113.
14. Demirci Ş, Gün C. Adipozdoku ve adipoz dokudan salınan bazı proteinler. MAKÜ Sağ Bil Enst Derg. 2017; 5(2):155-179.
15. Nigro E, Scudiero O, Monaco ML, et al. New insightin to adiponectin role in obesity and obesity-related diseases. Biomed Res Int. 2014; 658913.
16. Jutant EM, Tu L, Humbert M, et al. The thous and faces of leptin in the lung. Chest 2021; 159(1):239-248.
17. Ovsyannikova IG, White SJ, Larrabee BR, et al. Leptin and leptin-related gene polymorphisms, obesity, and influenza A/H1N1 vaccine-induced immune responses in older individuals. Vaccine 2021; 32(7):881-887.
18. Caër C, Rouault C, Le Roy T, et al. Immunecell-derivedcytokines contribute to obesity-related inflammation, fibrogenesis and metabolic deregulation in human adipose tissue. Sci Rep. 2017; 7(1):3000.
19. Del Turco S, Vianello A, Ragusa R, et al. COVID-19 and cardiovascular consequences: Is the endothelialdys function the hardest challenge?. Thromb Res. 2020; 196:143-151.
20. Jin Y, Ji W, Yang H, et al. Endothelial activation and dys function in COVID-19: from basic mechanismstopotential therapeuti capproaches. Signal Transduct Target Ther 2020; 5(1):293.
21. Iannelli A, Favre G, Frey S, et al. Obesityand COVID-19: ACE 2, the Missing Tile Obes Surg. 2020; 30(11):4615-4617.
22. Bansal R, Gubbi S, Muniyappa, R. Metabolic syndrome and covıd 19: endocrine-ımmune-vascular ınteractionsshapes clinical course. Endocrinology 2020; 161(10):112.
23. Alifano M, Alifano P, Forgez P, et al. Renin-angiotensin system at the heart of COVID-19 pandemic. Biochimie 2020; 174:30-33.
24. Amraei R, Rahimi N. COVID-19, Renin-angiotensin system and endothelialdys function. Cells 2020; 9(7):1652.
25. Widmer RJ, Lerman A. Endothelialdys function and cardiovascular disease. Glob Cardiol Sci Pract. 2014; (3):291-308.
26. Nishiga M, Wang DW, Han Y, et al. COVID-19 and cardiovascular disease: from basicmechanisms to clinical perspectives. Nature reviews. Cardiology 2020; 17(9):543-558.
27. Abrishami A, Eslami V, Baharvand Z, et al. Epicardial adipose tissue, inflammatory biomarkers and COVID-19: Is there a possible relation ship?. Int Immunopharmacol 2020; 90:107174.
28. Melo LC, Silva MA, Calles, AC. Obesity and lungfunction: a systematic review. Einstein2014; 12(1):120-125.
29. Steier J, Lunt A, Hart N, Observational study of the effect of obesity on lung volumes. Thorax 2014; 69(8):752-759.
30. Dixon AE, Peters U. Theeffect of obesity on lung function. Expert Rev Respir Med. 2018; 12(9):755-767.
31. Südy R, Peták F, Kiss L, et al. Obesity and diabetes: similarrespiratory mechanical but differentgas exchanged efects. Am J Physiol Lung Cell Mol Physiol. 2021; 320(3):l368-l376.
32. McDonald VM, Gibson P.G, Scott HA, et al. Shouldwetreat obesity in COPD? The effects of diet and resistance exercise training. Respirology 2016; 21(5):875-882.
33. Forno E, Han YY, Mullen J, et al. Over weight, obesity, and lung function in children and adultsameta-analysis. J Allergy Clin Immunol Pract. 2018; 6(2):570-581.
34. Sanchis-Gomar F, Lavie CJ, Mehra MR, et al. ObesityandOutcomes in COVID-19: When an Epidemic and Pandemic Collide. Mayo Clin Proc. 2020; 95(7):1445-1453.
35. Sant’Anna M, Jr Carvalhal, RF. Oliveira, et al. Respiratory mechanics of patients with morbidobesity. J Bras Pneumol. 2019; 45(5):e20180311.
36. Abumayyaleh M, NúñezGil IJ, El-Battrawy I, et al. Does there exist an obesity paradox in COVID-19? Insights of the international HOPE-COVID-19-registry. Obes Res Clin Pract. 2021; 15(3):275-280.
37. Hendren NS, de Lemos JA, Ayers C, et al. Association of Body Mass Index and Age With Morbidity and Mortality in Patients Hospitalized With COVID-19: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation 2021; 143(2):135-144.
38. Busetto L, Bettini S, Fabris R, et al. Obesityand COVID-19: An Italian Snapshot. Obesity. 2020; 28(9):1600-1605.
39. Hussain A, Mahawar K, Xia Z, et al. Obesity and mortality of COVID-19. Meta-analysis. Obes Res Clin Pract. 2020; 14(4):295-300.
40. Giacomelli A, Ridolfo AL, Milazzo L, et al. 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospectivecohort study. Pharmacol Res. 2020; 158:104931.
41. Hu J, Wang Y. The Clinical Characteristics and Risk Factors of Severe COVID-19. Gerontology 2021; 67(3):255-266.
42. Halvatsiotis P, Kotanidou A, Tzannis K, et al. Demographic and clinical features of criticallyill patients with COVID-19 in Greece: The burden of diabetes and obesity. Diabetes Res Clin Pract. 2020; 166:108331.
43. Greuel S, Ihlow J, Dragomir M.P, et al. COVID-19: Autopsy findings in six patients between 26 and 46 years of age. J Glob Infect Dis. 2021; 108:274-281. Advance online publication.
44. Elezkurtaj S, Greuel S, Ihlow J, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 2021; 11(1):4263.
45. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with corona virus disease 2019 in New York City: prospective cohort study. BMJ. 2020; 369:m1966.
46. Badedi M, Makrami A, Alnami A. Co-morbidity and blood group type risk in corona virus disease 2019 patients: A case-control study. J Infect Public Health. 2021; 14(4):550-554.
47. Biscarini S, Colaneri M, Ludovisi S, et al. The obesity paradox: analysis from thesmatteo COVID-19 Registry (SMACORE) cohort. Nutr Metab Cardiovasc Dis. 2020; 30(11):1920-1925.
48. Al Heialy S, Hachim MY, Hachim IY, et al. Combination of obesity and co-morbidities leads to unfavorable out comes in COVID-19 patients. Saudi J Biol Sci. 2021; 28(2):1445-1450.